Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis

Technology appraisal guidance
Reference number: TA127
Published: 22 August 2007
Last updated: 21 May 2024

Multiple sclerosis - natalizumab: Appendix A - provisional matrix of stakeholders

Multiple sclerosis - natalizumab: Appendix A - provisional matrix of stakeholders

Multiple sclerosis - natalizumab: Appendix A - provisional matrix of stakeholders
02 May 2013
(38.51 Kb 11 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 30 April 2013